Migraine Treatment Market Size to Exceed USD 7.0 Billion in 2034 and Register 6.6% CAGR

Vantage Market Research releases its latest comprehensive report on the ‘Global Migraine Treatment Market’ with a forecast period of 2025-2034. In 2023, the global migraine treatment market size was USD 3.7 billion, and is calculated at USD 3.94 billion in 2024. The market is calculated to reach USD 7.47 billion in 2034, and register a revenue CAGR of 6.6% over the forecast period (2025-2034).

Market Overview:

Revenue growth of the global migraine treatment market is expected to incline significantly over the forecast period, with a number of factors playing key roles currently, and more expected to emerge and drive market growth in future. Some key factors include rising prevalence of migraines among individuals of varying ages and demographics, increased focus on developing and introducing more efficient and effective treatments and therapies, drugs and devices, and rising awareness regarding availability of preventive solutions to reduce frequency and severity of attacks, and as a measure to enable higher response and efficacy to abortive therapy. 

In addition, technological advancements, innovations in Research and Development (R&D) in drugs and medications, therapeutics, devices, and personalized medicine to treat, prevent, and manage migraines, increasing product visibility and accessibility to Over-The-Counter (OTC) pain relievers and prescription medications, and advances in nasal sprays for acute migraine treatment and rapid results and outcomes are key factors supporting market revenue growth. 

Ongoing research into Calcitonin Gene-Related Peptide (CGRP) receptor antagonist nasal spray targeting therapies for migraine prevention is also expected to have major impact on growth of the migraine treatment market. Development of monoclonal antibodies targeting calcitonin gene-related peptide pathways as well as advancements in neuromodulation devices as non-invasive treatment for migraine are also key factors supporting revenue growth of the migraine treatment market. Moreover, rising focus on development of more effective and accurate diagnostic capabilities as well as innovations in biologics and wearable medical devices, more intensive research into migraine pathophysiology and targeted therapies, and development of personalized treatments are some trends in the market. 

Integration of Artificial Intelligence (AI), Machine Learning (ML), and analytics capabilities and tools are also expected to drive further breakthroughs in migraine diagnosis, analysis, triggers, treatment, and management. Such technological advancements are supporting epidemiological studies through gathering and provision of real-time data and enabling deeper insights into patient behaviors and outcomes. These factors are expected to continue to support growth of the migraine treatment market over the forecast period.

Some Key Takeaways:

• North America migraine treatment market accounted for largest revenue share in 2023, and the trend is expected to continue over the forecast period.
• Europe accounted for significantly large revenue share in 2023, with Germany and the UK accounting for major revenue shares respectively.
• Asia Pacific migraine treatment market is expected to register fastest revenue growth rate over the forecast period, with China, Japan, and India accounting for major revenue shares.
• The migraine without aura segment is expected to account for largest revenue share over the forecast period, as this type of migraine affects between 70% to 80% of sufferers, and diagnosis and treatment demand volumes are substantially high as a result. 
• The acute treatment segment is expected to account for largest revenue share among the treatment type segments over the forecast period, and growth is driven by need for immediate symptom relief among migraine sufferers and high demand due to efficacy of over-the-counter pain relievers, triptans, and newly developed CGRP inhibitors.
• The Over-The-Counter (OTC) segment is expected to continue to register largest revenue share among the product type segments over the forecast period, and is supported by ease, convenience, and accessibility to OTC medication.
• the oral segment accounted for largest revenue share among the other route of administration segments in 2023, and is expected to maintain dominance over the forecast period.
• The adult population segment among the patient demographics segments is expected to lead in terms of revenue share and revenue growth rate over the forecast period owing to high prevalence of migraines among adults aged 18-50 years.
• The hospitals and clinics segment is expected to account for largest revenue share and also the fastest revenue growth rate over the forecast period.
• The competitive landscape in the global migraine treatment market is characterized by a mix of established pharmaceutical companies, emerging biotech firms, and innovative medical device manufacturers.

Company List:

•             Pfizer Inc.

•             Eli Lilly and Company

•             Amgen Inc.

•             GlaxoSmithKline plc.

•             Novartis AG

•             Bayer AG

•             Allergan

•             Abbott

•             Allodynic Therapeutics, LLC

•             AbbVie

•             AOBiome

•             AstraZeneca

•             Aurobindo Pharma USA

•             Bausch Health Companies Inc.

•             Biohaven Pharmaceuticals

Recent Developments:

• May 8, 2024: AbbVie announced approval by Health Canada for its QULIPTA (atogepant) for the prevention of migraine for those adults suffering from minimum of four migraine days per month. QULIPTA is the first and only oral, small-molecule Calcitonin Gene-Related Peptide (CGRP) receptor antagonist approved to prevent both episodic and chronic migraine. Earlier on August 17, 2023, the company announced that it had received approval from the European Commission for AQUIPTA (atogepant), and prior to this on April 17, 2023, announced securing Food and Drug Administration (FDA) approval for expanding the indication of QULIPTA (atogepant) for preventive treatment of migraine in adults.  
• April 2, 2024: The Food and Drug Administration (FDA) has cleared WAT Medical’s HeadaTerm 2 as an OTC wearable Transcutaneous Electrical Nerve Stimulation (TENS) device for the prophylactic treatment of episodic migraine in patients 18 years of age and older. The rechargeable device adheres to the forehead of the user and releases targeted electrical impulses and acts on the supraorbital nerve and supratrochlear nerve, which is the nerves that transmit migraine pain. The design is simple and is controlled with a single button. Also, the HeadaTerm 2 is one of the only wearable anti-migraine devices available without a prescription in the US.